MX2024011298A - Métodos para tratar el sarcoma epitelioide recurrente con anticuerpos biespecíficos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1 - Google Patents
Métodos para tratar el sarcoma epitelioide recurrente con anticuerpos biespecíficos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1Info
- Publication number
- MX2024011298A MX2024011298A MX2024011298A MX2024011298A MX2024011298A MX 2024011298 A MX2024011298 A MX 2024011298A MX 2024011298 A MX2024011298 A MX 2024011298A MX 2024011298 A MX2024011298 A MX 2024011298A MX 2024011298 A MX2024011298 A MX 2024011298A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- methods
- muc16
- combination
- epithelioid sarcoma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320961P | 2022-03-17 | 2022-03-17 | |
| US202263350503P | 2022-06-09 | 2022-06-09 | |
| PCT/US2023/015347 WO2023177772A1 (en) | 2022-03-17 | 2023-03-16 | Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011298A true MX2024011298A (es) | 2024-12-06 |
Family
ID=86054295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011298A MX2024011298A (es) | 2022-03-17 | 2024-09-13 | Métodos para tratar el sarcoma epitelioide recurrente con anticuerpos biespecíficos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4493280A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025509567A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240159849A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119677534A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023236126A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245946A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315405A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011298A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023177772A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202617776A (zh) * | 2024-07-10 | 2026-05-01 | 美商再生元醫藥公司 | 治療smarcb1缺陷型癌症之方法 |
| CN119632993B (zh) * | 2024-12-04 | 2025-09-23 | 安徽医科大学 | 他泽司他在制备治疗急性肾损伤的药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| KR102531251B1 (ko) | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| JP7743314B2 (ja) * | 2019-06-21 | 2025-09-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
-
2023
- 2023-03-16 IL IL315405A patent/IL315405A/en unknown
- 2023-03-16 JP JP2024554783A patent/JP2025509567A/ja active Pending
- 2023-03-16 CN CN202380034697.1A patent/CN119677534A/zh active Pending
- 2023-03-16 WO PCT/US2023/015347 patent/WO2023177772A1/en not_active Ceased
- 2023-03-16 EP EP23718415.5A patent/EP4493280A1/en active Pending
- 2023-03-16 KR KR1020247033968A patent/KR20240159849A/ko active Pending
- 2023-03-16 AU AU2023236126A patent/AU2023236126A1/en active Pending
- 2023-03-16 CA CA3245946A patent/CA3245946A1/en active Pending
-
2024
- 2024-09-13 MX MX2024011298A patent/MX2024011298A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023177772A1 (en) | 2023-09-21 |
| EP4493280A1 (en) | 2025-01-22 |
| KR20240159849A (ko) | 2024-11-06 |
| IL315405A (en) | 2024-11-01 |
| CA3245946A1 (en) | 2023-09-21 |
| AU2023236126A1 (en) | 2024-09-19 |
| CN119677534A (zh) | 2025-03-21 |
| JP2025509567A (ja) | 2025-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003256A1 (es) | Métodos para el tratamiento del cáncer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecíficos. | |
| MA44146B1 (fr) | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer | |
| CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| CL2022002555A1 (es) | Anticuerpos anti-ccr8 para el tratamiento del cáncer | |
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| CL2021002645A1 (es) | Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos. (divisional de solicitud 201900726) | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| CL2021000131A1 (es) | Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos. | |
| PE20191661A1 (es) | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos | |
| MX2021013815A (es) | Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer. | |
| MX2024008055A (es) | Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1. | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| PE20230839A1 (es) | Agentes de union a lair-1 y metodos para su uso | |
| PE20230374A1 (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| MX2025001239A (es) | Métodos para tratar cáncer de próstata resistente a la castración metastasico con anticuerpos biespecíficos anti-psma x anti-cd28 en combinación con anticuerpos anti-pd-1 | |
| MX2024014019A (es) | Métodos para el tratamiento del cáncer de próstata resistente a la castración metastásico con anticuerpos biespecíficos anti-psma x anti-anticuerpos de cd3 solos o en combinación con anticuerpos anti-pd-1 | |
| MX2021009533A (es) | Composiciones y metodos para usar anticuerpos bispecificos para unirse al complemento y a un antigeno objetivo. | |
| MX2025010746A (es) | Metodos de tratamiento del cancer con moleculas biespecificas anti-cd22 x anti-cd28 | |
| MX2022014734A (es) | Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab. | |
| MX2025012459A (es) | Métodos para tratar el mieloma múltiple | |
| MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
| MX2024006187A (es) | Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4. | |
| IL315405A (en) | Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies | |
| AR125857A1 (es) | ANTICUERPOS PARA EL TRATAMIENTO DE a-SINUCLEINOPATÍAS | |
| AR134210A1 (es) | Agentes de unión anti-c2 y conjugados de estos |